New Horizons in ATTR-CM: Therapeutic Advances and Strategic Insights

Program Description

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a progressive condition caused by the misfolding of the transthyretin (TTR) protein, which aggregates into amyloid fibrils that deposit in tissues and organs, such as the heart, impairing their function and structural integrity. Although often underdiagnosed due to nonspecific symptoms and overlap with other conditions, ATTR-CM has become more manageable with the growing number of FDA-approved disease-modifying therapies (DMTs). Managed care pharmacists play a critical role in navigating the expanding therapeutic landscape by supporting the development of clinical guidelines to facilitate evidence-based treatment selection, evaluate cost-effectiveness, ensure timely patient access, and make formulary decisions aligned with current recommendations. This session will provide an in-depth review of diagnostic strategies, current and emerging therapies, and clinical guidelines in ATTR-CM to help pharmacists make informed treatment and management decisions. With a greater understanding of diagnostic tools, available therapies, and current clinical guidance, managed care professionals and pharmacists will be better equipped to support timely, appropriate therapy selection and improve patients’ overall quality of life.

Target Audience: Managed care pharmacists

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the burden of transthyretin amyloidosis cardiomyopathy (ATTR-CM) focusing on aspects such as patient quality of life, frequency of misdiagnosis, and the extent of health care resource use.
• Investigate current and emerging disease-modifying therapies for ATTR-CM by reviewing clinical guidelines, mechanisms of action, dosing strategies, administration considerations, and safety profiles
• Determine strategies to address the burden of high health care utilization in ATTR-CM by enhancing multidisciplinary care coordination and improving patient access to appropriate therapies within managed care settings